Learning from tesaglitazar
Diab Vasc Dis Res 2007 4: 161-162. [PDF] [References] [Request Permission]  

Michel Marre and Abdoulaye Leye

Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity
Diab Vasc Dis Res 2007 4: 163-173. [Abstract] [PDF] [References] [Request Permission]  

Bjorn Fagerberg, Herbert Schuster, Grethe Støa Birketvedt, Serena Tonstad, Karl Peter Öhman, and Ingrid Gause-Nilsson

Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPAR/ agonist, tesaglitazar
Diab Vasc Dis Res 2007 4: 174-180. [Abstract] [PDF] [References] [Request Permission]  

Harold Bays, Jennifer McElhattan, and Brian S Bryzinski

A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus
Diab Vasc Dis Res 2007 4: 181-193. [Abstract] [PDF] [References] [Request Permission]  

John PH Wilding, Ingrid Gause-Nilsson, and Anders Persson

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes
Diab Vasc Dis Res 2007 4: 194-203. [Abstract] [PDF] [References] [Request Permission]  

Burkhard Göke, Ingrid Gause-Nilsson, and Anders Persson

The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes
Diab Vasc Dis Res 2007 4: 204-213. [Abstract] [PDF] [References] [Request Permission]  

Robert E Ratner, Shamik Parikh, and Conrad Tou

Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes
Diab Vasc Dis Res 2007 4: 214-221. [Abstract] [PDF] [References] [Request Permission]  

Shailja V Parikh, Shuaib M Abdullah, Ellen C Keeley, Joaquin E Cigarroa, Tayo A Addo, John J Warner, Amit Khera, James A De Lemos, and Darren K McGuire

Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK
Diab Vasc Dis Res 2007 4: 222-225. [Abstract] [PDF] [References] [Request Permission]  

Gabriele Perriello, Simone Pampanelli, Paolo Brunetti, Cinzia Di Pietro, and Segundo Mariz

Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes
Diab Vasc Dis Res 2007 4: 226-230. [Abstract] [PDF] [References] [Request Permission]  

Mensud Hatunic, Francis Finucane, Nicole Burns, Declan Gasparro, and John J Nolan

Vascular inflammatory markers in early-onset obese and type 2 diabetes subjects before and after three months' aerobic exercise training
Diab Vasc Dis Res 2007 4: 231-234. [Abstract] [PDF] [References] [Request Permission]  

Erika Martínez-López, Bertha Ruíz-Madrigal, Iván Hernández-Cañaveral, and Arturo Panduro

Association of the T54 allele of the FABP2 gene with cardiovascular risk factors in obese Mexican subjects
Diab Vasc Dis Res 2007 4: 235-236. [Abstract] [PDF] [References] [Request Permission]  

Vanitha Singaram and Richard Pratley

The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
Diab Vasc Dis Res 2007 4: 237-240. [Abstract] [PDF] [References] [Request Permission]  

Uditha Bulugahapitiya, Sajith Siyambalapitiya, Jabulani Sithole, Devaka Fernando, and Iskandar Idris

Coexistence of smoking and metabolic syndrome among middle-aged patients with diabetes in the UK: a cross-sectional analysis
Diab Vasc Dis Res 2007 4: 241-242. [PDF] [References] [Request Permission]  

To see an article, click its [PDF] link. To add articles to your marked citations, check the boxes to the left of the titles you want, and click the 'Add to Marked Citations' button. To see one abstract at a time, click its [Abstract] link.